In 2011, she joined the institution's molecular diagnostics laboratory where she has been developing translational next
generation sequencing assays and bioinformatics workflows for the Molecular Tumor Profiling Lab of the Yale Cancer Center.
Our pioneering next -
generation sequencing assay kits and software are revolutionizing the detection of clonality, somatic hypermutation, and minimal residual disease (MRD).
We report a third -
generation sequencing assay on nanopore technology (MinION) for detecting BCR - ABL1 KD mutations and compare the results to a Sanger sequencing (SS)- based test in 24 Philadelphia - positive (Ph +) leukemia cases.
Not exact matches
The LymphoTrack TRB
Assay completes the comprehensive menu of Invivoscribe LymphoTrack Clonality
Assays which enable rapid clonal rearrangement identification with the unparalleled accuracy and sensitivity of next
generation sequencing (NGS).
As a reagent manufacturer, we offer a comprehensive selection of gel, capillary, and next -
generation sequencing PCR
assays for gene rearrangement, chromosome translocation, and gene mutation detection as analyte specific reagents (United States), research use only, or CE - marked in vitro diagnostics to laboratories (outside of North America).
These RUO
assays, developed for use with the leading Next -
Generation Sequencing (NGS) platforms, include optimized multiplex PCR master mixes with primers incorporating both platform specific adapters, and specimen tracking Seq ID tags for single step workflow.
The LymphoTrack ® Dx TRB
Assay for the Illumina MiSeq ® is an in vitro diagnostic product intended for next -
generation sequencing (NGS) based determination of the frequency distribution of TRB gene rearrangements in patients suspected with having lymphoproliferative disease.
The RNA integrity number (RIN) was determined using The Agilent RNA ScreenTape
assay (Agilent 2200 TapeStation, Salk Institute's Next
Generation Sequencing core), and high quality RNA was used for RNA - Seq.
Currently, Vaijayanti leads Strand's translational clinical research team that designs and validates next -
generation sequencing and molecular
assays for Strand's clinical diagnostics offering in personalized medicine.
SAN DIEGO, March 28, 2017 (GLOBE NEWSWIRE)-- Invivoscribe ® Technologies Inc., a global company with decades of experience providing internationally standardized clonality and biomarker testing solutions for the fields of oncology, personalized molecular diagnostics ®, and personalized molecular medicine ®, reports that its next -
generation sequencing (NGS) LymphoTrack ®
Assay kits are being used by its LabPMM ® clinical laboratories, pharmaceutical partners, and cancer centers to identify and monitor chimeric antigen receptor T - cells (CAR - T) and engineered T - cell receptors in peripheral blood of subjects in support of immuno - therapeutic drug development and treatment regimen development for both hematologic and solid tumors.
«In this study we applied the method to bacterial 16S
sequencing but since the
generation of these libraries is easy, flexible and cost effective — no fancy fluidics equipment or chemical synthesis of specific barcodes is needed — we are currently applying the
assay in a number of other projects.
These
assays, developed for use with specific Next
Generation Sequencing (NGS) platforms, combine optimized, proprietary multiplex PCR master mixes with a software package that converts NGS output data to an easily interpretable form, enabling you to identify the DNA
sequence, clonal prevalence, and V - J gene identity for each gene rearrangement.
MELGEN groups have shown that mutation screening, gene expression (using the Illumina cDNA - mediated Annealing, Selection, extension, and Ligation (DASL)
Assay) platform and state of the art next
generation sequencing can be applied successfully to small formalin fixed paraffin embedded (FFPE) tumours.